Agilent Technologies Inc (A) carries a ŷRobot AI score of 47 out of 100. The model's fair value estimate is $153.75, 12.2% below the last close of $175.03. The chart signal reads Sell.
| Metric | A |
|---|---|
| AI score | 47 / 100 |
| Chart signal | Sell |
| Fair value estimate | $153.75 |
| Upside to fair value | -12.2% |
| Previous close | $175.03 |
| P/E | 31.08 |
| Price / sales | 5.87 |
| Market cap | $49.40B |
| EPS | 4.95 |
| Revenue growth | -0.0% |
| 1-year price change | 0.3% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR.
As of Sep 29, 2026, ŷRobot's fair-value model estimates Agilent Technologies Inc (A) at $153.75 against a last close of $175.03, implying 12.2% downside to the model's estimate.
The chart-signal model classifies A as Neutral as of Sep 29, 2026, with a signal score of -0.15 on a -1 to 1 scale.
A scores 47 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Sep 29, 2026.
A trades at 31.1 times earnings and 5.9 times sales as of Sep 29, 2026.
ŷRobot's seasonal forecast curve for A reads +2.2% at 30 days, +6.8% at 90 days, and +0.3% at one year as of Sep 29, 2026. Seasonal tendencies are historical patterns, not predictions.
Agilent Technologies Inc's revenue growth is -0.0% and free-cash-flow growth is -41.8% on the latest reported figures.
A chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.